Amylyx Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2025: USD -206.98 M

Amylyx Pharmaceuticals, Inc. Operating Cash Flow is USD -206.98 M for the Trailing 12 Months (TTM) ending March 31, 2025, a -1,354.28% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Amylyx Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 16.50 M, a -111.44% change year over year.
  • Amylyx Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2023 was USD -144.31 M, a 40.39% change year over year.
  • Amylyx Pharmaceuticals, Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -102.79 M.
Key Data
Date Operating Cash Flow Capital Expenditure Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities